X4 Pharmaceuticals Inc (NASDAQ: XFOR) kicked off on Monday, down -5.60% from the previous trading day, before settling in for the closing price of $0.39. Over the past 52 weeks, XFOR has traded in a range of $0.26-$1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.00%. While this was happening, its average annual earnings per share was recorded 77.49%. With a float of $117.21 million, this company’s outstanding shares have now reached $168.51 million.
Considering the fact that the conglomerate employs 93 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 85.2%, operating margin of -618.81%, and the pretax margin is -398.61%.
X4 Pharmaceuticals Inc (XFOR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of X4 Pharmaceuticals Inc is 31.28%, while institutional ownership is 35.55%. The most recent insider transaction that took place on Nov 15 ’24, was worth 12,583. In this transaction President and CEO of this company sold 31,897 shares at a rate of $0.39, taking the stock ownership to the 993,919 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Officer proposed sale 31,897 for $0.41, making the entire transaction worth $13,078.
X4 Pharmaceuticals Inc (XFOR) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.1 earnings per share (EPS), higher than consensus estimate (set at -0.15) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 77.49% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
Take a look at X4 Pharmaceuticals Inc’s (XFOR) current performance indicators. Last quarter, stock had a quick ratio of 4.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Compared to the last year’s volume of 2.35 million, its volume of 1.36 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 79.57%. Additionally, its Average True Range was 0.06.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 17.23%, which indicates a significant decrease from 26.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 369.04% in the past 14 days, which was higher than the 154.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5146, while its 200-day Moving Average is $0.8235. Nevertheless, the first resistance level for the watch stands at $0.3940 in the near term. At $0.4170, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4340. If the price goes on to break the first support level at $0.3540, it is likely to go to the next support level at $0.3370. Now, if the price goes above the second support level, the third support stands at $0.3140.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
The company with the Market Capitalisation of 63.85 million has total of 170,546K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -101,170 K annual income. Company’s last quarter sales were recorded 560 K and last quarter income was -36,700 K.
